Renaissance Technologies
BRNS

Renaissance Technologies’s Barinthus Biotherapeutics BRNS Stock Holding History

Renaissance Technologies’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.5K Sell
25,000
-126,000
-83% -$82.1K ﹤0.01% 3106
2026
Q1 		$85.9K Buy
151,000
+7,900
+6% +$5.21K ﹤0.01% 3050
2025
Q4 		$100K Buy
143,100
+76,800
+116% +$76.7K ﹤0.01% 3014
2025
Q3 		$82.9K Buy
66,300
+30,000
+83% +$37.5K ﹤0.01% 3277
2025
Q2 		$33.8K Buy
36,300
+600
+2% +$524 ﹤0.01% 3429
2025
Q1 		$34.7K Buy
35,700
+600
+2% +$616 ﹤0.01% 3325
2024
Q4 		$42.4K Buy
35,100
+7,200
+26% +$8.38K ﹤0.01% 3411
2024
Q3 		$33.2K Buy
27,900
+2,800
+11% +$3.76K ﹤0.01% 3389
2024
Q2 		$35.1K Sell
25,100
-2,600
-9% -$5.87K ﹤0.01% 3324
2024
Q1 		$66K Sell
27,700
-1,999
-7% -$5.64K ﹤0.01% 3441
2023
Q4 		$110K Buy
29,699
+8,299
+39% +$28K ﹤0.01% 3282
2023
Q3 		$66K Sell
21,400
-12,600
-37% -$27.1K ﹤0.01% 3341
2023
Q2 		$70K Buy
34,000
+22,600
+198% +$53.5K ﹤0.01% 3549
2023
Q1 		$26K Buy
+11,400
New +$31.7K ﹤0.01% 3779

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
GP
GLR Partners Columbia, Maryland $215M AUM
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.5B AUM 13.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Renaissance Technologies's BRNS Position: Q2 2026 in Review

Renaissance Technologies reduced its Barinthus Biotherapeutics (BRNS) stake by 83% in Q2 2026, selling an estimated $82.1K and leaving 25,000 shares worth $16.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3106.

Renaissance Technologies first reported a position in BRNS in Q1 2023 and has held it in 14 quarters since. The position peaked at $110K in Q4 2023. 15 funds tracked by Wall St. Rank hold BRNS as of Q2 2026.

  • Renaissance Technologies held 25,000 shares of Barinthus Biotherapeutics worth $16.5K as of Q2 2026.
  • Renaissance Technologies sold 126,000 Barinthus Biotherapeutics shares in Q2 2026, an estimated $82.1K.
  • Barinthus Biotherapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #3106 holding.
  • Renaissance Technologies first reported a position in Barinthus Biotherapeutics in Q1 2023 and has held it in 14 quarters since.
  • Renaissance Technologies's Barinthus Biotherapeutics position peaked at $110K in Q4 2023.
  • 15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.